Back to List View Graph View

Dasatinib

Dasatinib is a second-generation, orally bioavailable tyrosine kinase inhibitor (TKI) developed primarily for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Where the papers sit

14 papers from the last 6 months study dasatinib directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 5 observational · 9 preclinical

Themes 3 themes · 1 new direction

  • Cellular Senescence and Inflammation

    Cellular senescence is being linked to inflammation, impaired stem-cell function, metabolic dysfunction and tissue degeneration. Dasatinib-related interventions target senescent T cells or adipocytes, with MAPK14/NF-κB and uPAR pathways recurring. Other work connects senescence with sickle-cell disease, muscle atrophy and posttraumatic osteoarthritis. The field remains mechanistically broad, with senescence reduction pursued as a way to restore tissue and immune function.

    6 papers · 42.9%

  • Chronic Myeloid Leukemia Outcomes

    Chronic myeloid leukemia care is moving toward longitudinal molecular response monitoring alongside treatment safety surveillance. BCR-ABL1 transcript decline velocity and international-scale measurements are used to interpret TKI response and switching. Cardiovascular assessment recurs through echocardiography and arterial-stiffness testing, while proton pump inhibitor use may influence dasatinib treatment changes. Rare complications such as cervicofacial oedema remain part of ongoing risk characterization.

    5 papers · 35.7%

  • Localized Antitumor Immunotherapy

    pH-sensitive hydrogels and albumin nanoparticles are being used to localize dasatinib at residual tumors. Melanoma studies emphasize local eradication while limiting systemic exposure. Timed dasatinib priming can reduce MHC class I inhibition of NK and anti-CD19 CAR-NK cells. The work is moving toward combining targeted delivery with improved innate immune cytotoxicity.

    3 papers · 21.4%

NEW DIRECTION

Dasatinib emerges as a reversible regulator of lymph-node perfusion and lymphocyte trafficking

The paper on peripheral lymph nodes begins with the unresolved question of how dasatinib affects lymphocyte surveillance beyond the spleen. Instead of merely serving as a leukemia treatment or immune-cell modulator, dasatinib caused transient inhibition of T- and B-cell motility by inducing vasoconstriction, lymph-node hypoxia, and reduced interstitial movement in vivo; ROCK inhibition reversed the hypoxia and rescued CD8+ T-cell motility 42555708Aug. This identifies dasatinib as a reversible regulator of lymph-node vascular physiology and immune-cell trafficking, opening a direction distinct from the therapeutic, senolytic, and ex vivo cell-engineering roles represented elsewhere in the set.

dasatinib chemical structure

Papers

The 14 papers from the last 6 months that study dasatinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Cellular Senescence and Inflammation (6)
  1. Dasatinib alleviates inflammation in sepsis by inhibiting T cell senescence via MAPK14 /NF-κB axis. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 17 Aug 2026 PMID 42607350
  2. Dasatinib reversibly disrupts T cell motility and activation in lymph nodes. Science advances · 5 Aug 2026 PMID 42555708
  3. Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans. Science translational medicine · 22 Jul 2026 PMID 42485438
  4. Enhancing insulin sensitivity by reducing adipocyte senescence using uPAR-targeted nanoparticles in high-fat-diet-induced obese mice. Journal of controlled release : official journal of the Controlled Release Society · 13 Jul 2026 PMID 42442548
  5. Integrative multi-omics and machine learning reveal PLAUR as a Pan-Cancer prognostic biomarker and potential therapeutic target. Bioorganic chemistry · 2 Jul 2026 PMID 42391812
  6. Cellular senescence links muscle atrophy and posttraumatic osteoarthritis after ACL injury. Function (Oxford, England) · 25 Jun 2026 PMID 42348390
Chronic Myeloid Leukemia Outcomes (5)
  1. Dasatinib-induced cervicofacial oedema in chronic myeloid leukaemia blast crisis. BMJ case reports · 19 Aug 2026 PMID 42618311
  2. Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study. Leukemia research · 4 Aug 2026 PMID 42551129
  3. Association between proton pump inhibitor co-medication and treatment switching in dasatinib-treated patients with chronic myeloid leukemia: a German real-world evidence study. Annals of hematology · 30 Jul 2026 PMID 42530652
  4. Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study. Cancer · 15 Jul 2026 PMID 42455913
  5. A Comprehensive Echocardiographic Assessment of Patients With Chronic Myeloid Leukemia on Dasatinib. Echocardiography (Mount Kisco, N.Y.) · 28 May 2026 PMID 42206579
Localized Antitumor Immunotherapy (3)
  1. Timing-dependent dasatinib priming attenuates MHC class I-mediated inhibition of NK cells and CAR-NK cells. Oncoimmunology · 14 Nov 2026 PMID 43033140
  2. Construction of pH-Sensitive Dynamic Composite Hydrogels and Their Local Targeted Antitumor Research. ACS applied bio materials · 27 Oct 2026 PMID 42945386
  3. Dasatinib-Loaded Human Serum Albumin Nanoparticle-Impregnated Hydrogel for Localised Eradication of Residual Melanoma: Integrated In Silico, 3D Spheroid, and Dermatokinetic Evaluation. ACS applied bio materials · 17 Aug 2026 PMID 42606056

By study type

Observational studies and case reports (5)
  1. Dasatinib-induced cervicofacial oedema in chronic myeloid leukaemia blast crisis. BMJ case reports · 19 Aug 2026 PMID 42618311
  2. Arterial stiffness in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: An exploratory prospective observational study. Leukemia research · 4 Aug 2026 PMID 42551129
  3. Association between proton pump inhibitor co-medication and treatment switching in dasatinib-treated patients with chronic myeloid leukemia: a German real-world evidence study. Annals of hematology · 30 Jul 2026 PMID 42530652
  4. Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study. Cancer · 15 Jul 2026 PMID 42455913
  5. A Comprehensive Echocardiographic Assessment of Patients With Chronic Myeloid Leukemia on Dasatinib. Echocardiography (Mount Kisco, N.Y.) · 28 May 2026 PMID 42206579
Preclinical: animal, cell and lab studies (9)
  1. Timing-dependent dasatinib priming attenuates MHC class I-mediated inhibition of NK cells and CAR-NK cells. Oncoimmunology · 14 Nov 2026 PMID 43033140
  2. Construction of pH-Sensitive Dynamic Composite Hydrogels and Their Local Targeted Antitumor Research. ACS applied bio materials · 27 Oct 2026 PMID 42945386
  3. Dasatinib alleviates inflammation in sepsis by inhibiting T cell senescence via MAPK14 /NF-κB axis. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 17 Aug 2026 PMID 42607350
  4. Dasatinib-Loaded Human Serum Albumin Nanoparticle-Impregnated Hydrogel for Localised Eradication of Residual Melanoma: Integrated In Silico, 3D Spheroid, and Dermatokinetic Evaluation. ACS applied bio materials · 17 Aug 2026 PMID 42606056
  5. Dasatinib reversibly disrupts T cell motility and activation in lymph nodes. Science advances · 5 Aug 2026 PMID 42555708
  6. Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans. Science translational medicine · 22 Jul 2026 PMID 42485438
  7. Enhancing insulin sensitivity by reducing adipocyte senescence using uPAR-targeted nanoparticles in high-fat-diet-induced obese mice. Journal of controlled release : official journal of the Controlled Release Society · 13 Jul 2026 PMID 42442548
  8. Integrative multi-omics and machine learning reveal PLAUR as a Pan-Cancer prognostic biomarker and potential therapeutic target. Bioorganic chemistry · 2 Jul 2026 PMID 42391812
  9. Cellular senescence links muscle atrophy and posttraumatic osteoarthritis after ACL injury. Function (Oxford, England) · 25 Jun 2026 PMID 42348390